Project aims to develop a prognostic test to improve prediction of ALS disease progression
More than one-third of study participants in Phase 2 Study were Cord Blood Registry® (CBR®) clients.
Preoperative Planning Tool Has the Potential for Changing the Management of Cerebral Aneurysm Treatment
Roche (SIX: RO, ROG; OTCQX:RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved the VENTANA ALK (D5F3) CDx Assay1 for use on the VENTANA BenchMark ULTRA automated slide stainer. The assay is a companion diagnostic to aid in the identification of ALK-positive lung cancer patients who are eligible for treatment with Pfizer’s FDA-approved therapy XALKORI®(crizotinib).
EpiFinder offers a proven tool that empowers people to take ownership of their health, connect with their doctor, advance epilepsy and neurology research and is telling their story on KickStarter.
Reducing cardiovascular disease and complications among Hispanic diabetes patients in Arizona is the focus of a new research project for Tomas Nuño, PhD, assistant professor of public health practice and translational research at the UA Mel and Enid Zuckerman College of Public Health – Phoenix and the Department of Emergency Medicine at the UA College of Medicine – Tucson
NASA grant will allow the Center for Applied NanoBioscience and Medicine to study the health effects of long space missions
Second study to probe whether an investigational drug can prevent or delay the emergence of symptoms in high-risk older adults
The Arizona Commerce Authority has announced the 25 semifinalists in the Fall 2017 round of the Arizona Innovation Challenge. The semifinalists include: Breezing Co. (Tempe), GT Medical Technologies (Gilbert), Life365 Inc. (Tempe), Merchant’s Garden AgroTech Inc. (Tucson), MicronView LLC (Tucson), NanoPin Technologies Inc. (Phoenix), Resonea (Scottsdale), SkinSafe Inc. (Scottsdale), and VB Cosmetics Inc. (Chandler).
Stephen Munk has joined the Biodesign Institute at Arizona State University as deputy director of science and technology. In this role, Munk will focus on the strategic, business and technical operations of Arizona’s single largest bioscience research infrastructure investment.
A University of Arizona Cancer Center and College of Agriculture and Life Sciences research team is engaged in a series of studies to investigate how genistein, a component of soy foods, might suppress the development of breast cancer.
Tucson, Ariz. – Researchers in the University of Arizona College of Medicine – Tucson have invented a new class of non-opioid compounds to treat pain. Animal testing has shown that the drug candidates are more effective than morphine, non-addictive, and non-toxic at high doses. The UA has licensed the compounds to startup Regulonix.
The University of Arizona has licensed a drug that aims to shorten the lives of cancer cells to startup Reglagene. The technology, invented at the UA College of Pharmacy and the UA BIO5 Institute by Laurence Hurley, PhD, and Vijay Gokhale, PhD, has been shown to be effective in shortening the lives of target cells, essentially inducing cancer cells to grow old and die.
Through its empathy-driven innovation model, NeoLight develops technologies that treat infants with life threatening medical conditions.
